Vendor Intelligence Report: Xingruida XDR

Executive summary

Across 73 Finnrick lab tests, Xingruida XDR has a 68% overall pass rate, with 50 pass and 23 fail. The signal is uneven rather than vendor-wide clean or vendor-wide bad. Retatrutide and Tirzepatide are the most defensible choices inside the tested catalog, but both still require current-lot verification; Tesamorelin is the clearest retreat product, and GHK-Cu shows why the middle of the catalog cannot be treated as a blind buy. Ratings also compress under stricter grading.

The corporate record is young and thin. UK filings identify a recent Xingruida Trade Co., Ltd. with a China-based 75%+ control person, a mass-registration UK address, overdue compliance items and no verified UK operating substance. A Hong Kong entity predates it, but the director trail was not resolved in the source set, leaving the buyer-recourse path more ambiguous than the site presentation suggests.

The web trail adds a separate credibility problem: hkxingruida.com was registered in 2025, while the site carries 2016-dated news posts. The report also traces a sister-brand lead where another peptide storefront shares IP, registrar, 4cun nameservers and the same Classic ASP/IIS template family. That overlap points to a coordinated export-site pattern, not proven identical ownership.

Buyer-authentication signals are modest: sparse About content, no captured physical address on the contact page, rotating Hong Kong phone numbers, empty privacy pages and a single displayed Janoshik COA whose automated portal verification could not be completed. The promotion scan found no public coupon-code network, so the core question is batch validation and accountability, not visible influencer hype.

Inside the full report:

• Per-product pass/fail rates, spark-grid trajectories and methodology-divergence charts for all 6 tested products
• Companies House exhibits for Xingruida Trade Co., Ltd., the named PSC and overdue UK compliance flags
• Hong Kong entity trail for Hong Kong Xingruida Trading Co., Limited and the unresolved director gap
• Wayback/domain timeline comparing the 2025 domain record with 2016-dated site content
• Infrastructure comparison of hkxingruida.com and Mammoth Biotech: shared IP, 4cun nameservers and Classic ASP/IIS template
• Contact, payment and authentication review covering phone-number rotation, empty privacy pages, COA limits and affiliate-scan blind spots

Risk assessment

• Tesamorelin quality risk — high: Finnrick records show Tesamorelin at 45.89% across 7 tests (3 pass / 4 fail), the weakest tested product in Xingruida’s catalog.
• Borderline quality risk in BPC-157, GHK-Cu and Melanotan II — medium: BPC-157 is 54.65% across 8 tests, GHK-Cu is 66.85% with 4 pass / 5 fail, and Melanotan II is 58.59% across only 2 tests; require lot-specific verification.
• Batch-validation risk on Retatrutide and Tirzepatide — medium: Retatrutide 80.79% and Tirzepatide 76.66% are Xingruida’s strongest tested products, but each has 5 recorded failures, so verify the current batch.
• Corporate accountability and shell-entity risk — high: UK company uses a mass-registration address, filings/identity verification are overdue, Hong Kong directors were not identified, and no manufacturing-site ownership was verified.
• Multi-brand sourcing opacity risk — medium: Mammoth Biotech shares IP, registrar, nameservers and ASP/IIS template indicators with hkxingruida.com, but the relationship and source manufacturer are not disclosed.
• Misleading operating-history risk — medium: News/blog posts show 2016 dates on a domain registered in March 2025, consistent with recycled or backdated template content rather than verified longevity.
• Brand-confusion and authenticity-verification risk — medium: Multiple Hong Kong phone numbers, an unrelated XRD/Xinruida TikTok collision, no official-channel list and no anti-counterfeit procedure make misdirection harder to detect.